A groundbreaking dual CAR T cell therapy, which targets both CD19 and CD38 proteins, has progressed to Phase 1/2 clinical trials. This innovative approach aims to effectively treat complex autoimmune disorders affecting multiple body systems. The therapy's advancement indicates promising potential for addressing such conditions.